Safety and Effects of PF-08103402 in Healthy Adults and Adults with Mild to Moderate Asthma A Phase 1 Study with Oral Suspension and Tablets

What this Trial Is About

Researchers are studying the safety and effects of a new medicine called PF-08103402 in healthy adults and adults with mild-to-moderate asthma. This Phase 1 trial aims to understand how the body processes this medicine, how much reaches the bloodstream, how food and other medicines affect it, and how the medicine leaves the body. The study includes healthy volunteers and adults diagnosed with asthma, evaluating different doses and formulations. The study has six parts named A through F. Participants take PF-08103402 as an oral suspension or tablet once daily, with some parts requiring 14 days of dosing and others a single dose. There are optional groups for Japanese participants and adults with asthma. Some parts also test the medicine with other drugs like midazolam. The length of participation varies by study part, ranging from about 9 to 16 weeks. Participants will visit the study clinic multiple times and have overnight stays ranging from 10 to 28 nights depending on the part. They will undergo examinations including physical checks, heart tests ECG, blood and urine tests, breathing tests for asthma patients, stool samples, vital signs monitoring, and questionnaires. The study team will also call participants at the end of the study to assess their health. Researchers will measure safety outcomes like adverse events and how the medicine behaves in the body.

A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma